Potential Drug Target and Biomarker for CHTF18 (G63922)

Target Name: CHTF18

NCBI ID: G63922

CHTF18

Potential Drug Target and Biomarker for CHTF18

CHTF18 (C321D2.4) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidneys. Its full name is calbindin-related protein F18, and it is a type of cytoskeletal protein that is Characterized by the presence of a calbindin-like domain.

Calbindin is a protein that is composed of two heavy chains and two light chains. The heavy chains contain a variable region that is responsible for the protein's stability and the light chain contains a variable region that is responsible for the protein's localization. Calbindin is a well -known protein that is involved in a variety of cellular processes, including cell adhesion, migration, and signaling.

CHTF18 is a variant of the calbindin gene that has been identified as a potential drug target. The C321D2.4 variation refers to a specific amino acid substitution in the calbindin gene that results in the production of a protein with altered properties. This variant has been shown to have decreased activity in a variety of cellular processes, including cell adhesion and migration.

Research has also shown that CHTF18 is involved in the regulation of cellular processes that are important for the development and progression of a variety of diseases, including cancer. For example, studies have shown that CHTF18 is involved in the regulation of cell proliferation, cell survival. , and the formation of blood vessels in cancer cells.

In addition to its potential as a drug target, CHTF18 is also a potential biomarker for a variety of diseases. For example, studies have shown that CHTF18 is often reduced in the blood of people with various diseases, including cancer, diabetes, and neurodegenerative disorders . Additionally, CHTF18 has been shown to be involved in the regulation of cellular processes that are important for the development and progression of these diseases, which suggests that it may be a useful biomarker for monitoring the effectiveness of treatments for these conditions.

Overall, CHTF18 is a protein that is characterized by its ability to localize to various tissues and its involvement in a variety of cellular processes. Its potential as a drug target and as a biomarker make it an attractive target for further research and development.

Please note that this article is not a substitute for professional medical advice and should not be used as such.

Last update: 2023-01-29

1000-word article about CHTF18 (C321D2.4), a potential drug target and biomarker.

CHTF18 (C321D2.4), also known as calbindin-related protein F18, is a cytoskeletal protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidneys. Its full name is calbindin- related protein F18, and it is characterized by the presence of a calbindin-like domain. Calbindin is a protein composed of two heavy chains and two light chains, with the heavy chains containing a variable region responsible for the protein's stability and the light chain containing a variable region responsible for the protein's localization.

CHTF18 is a variant of the calbindin gene that has been identified as a potential drug target. The C321D2.4 variation refers to a specific amino acid substitution in the calbindin gene that results in the production of a protein with altered properties (5 ). This variant has been shown to have decreased activity in a variety of cellular processes, including cell adhesion and migration.

In addition to its potential as a drug target, CHTF18 is also a potential biomarker for a variety of diseases. For example, studies have shown that CHTF18 is often reduced in the blood of people with various diseases, including cancer, diabetes, and neurodegenerative disorders.

Protein Name: Chromosome Transmission Fidelity Factor 18

Functions: Chromosome cohesion factor involved in sister chromatid cohesion and fidelity of chromosome transmission. Component of one of the cell nuclear antigen loader complexes, CTF18-replication factor C (CTF18-RFC), which consists of CTF18, CTF8, DCC1, RFC2, RFC3, RFC4 and RFC5. The CTF18-RFC complex binds to single-stranded and primed DNAs and has weak ATPase activity that is stimulated by the presence of primed DNA, replication protein A (RPA) and by proliferating cell nuclear antigen (PCNA). The CTF18-RFC complex catalyzes the ATP-dependent loading of PCNA onto primed and gapped DNA. Interacts with and stimulates DNA polymerase POLH. During DNA repair synthesis, involved in loading DNA polymerase POLE at the sites of local damage (PubMed:20227374)

The "CHTF18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHTF18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets